We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

3 Trial Losses Won't Doom Xarelto Patients

Law360, New York (August 23, 2017, 12:47 PM EDT) -- After a hat trick of defense wins for Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. in bellwether trials over blood thinner Xarelto, consumers face an uphill...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.